EPS Bio Technology Corp. (TPEX:4183)
13.25
-1.20 (-8.30%)
Nov 20, 2026, 1:30 PM CST
EPS Bio Technology Revenue
EPS Bio Technology had revenue of 92.16M TWD in the quarter ending September 30, 2026, a decrease of -29.42%. This brings the company's total for the last twelve months to 380.33M, down -23.50% year-over-year. In the year 2025, EPS Bio Technology had annual revenue of 499.70M with 10.78% growth. That makes EPS Bio Technology the 36,782nd largest company in the world by revenue and 1,925th in Taiwan.
Revenue (ttm)
380.33M
Revenue Growth
-23.50%
P/S Ratio
0.83
Revenue / Employee
3.52M
Employees
108
Market Cap
315.35M
Revenue by Geography
- Germany 206.87M 41.4%
- Iran 114.47M 22.9%
- Others 75.68M 15.1%
- Saudi Arabia 51.67M 10.3%
- United States 26.43M 5.3%
- Switzerland 24.60M 4.9%
Fiscal year ended Dec 31, 2025 See the full EPS Bio Technology breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 499.70M | 48.62M | 10.78% |
| Dec 31, 2024 | 451.08M | -19.08M | -4.06% |
| Dec 31, 2023 | 470.17M | 6.72M | 1.45% |
| Dec 31, 2022 | 463.45M | -16.83M | -3.50% |
| Dec 31, 2021 | 480.28M | 2.68M | 0.56% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cowealth Medical Holding | 2.95B |
| Diamond Biotechnology | 464.63M |
| Radiant Innovation | 417.97M |
| Health & Life | 388.28M |
| Taiwan Advanced Nanotech | 170.57M |
| PlexBio | 137.57M |
| iXensor | 26.67M |
| AmCad BioMed | 26.16M |